General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
This Is the Cheapest AI Stock I Know | news.google.com • |
China Stock Ideas For Tech Resurgence: Tesla, Apple Make Strategic Moves; Goldman Sachs Projects 40% Upside ... | news.google.com • |
Baidu snaps six-day winning streak (NASDAQ:BIDU) | news.google.com • |
Baidu snaps six-day winning streak (NASDAQ:BIDU) | news.google.com • |
Discount Alert! 7 Hot Stocks Heading for the Clearance Rack. | investorplace.com • |
Tesla Turnaround in the Cards? Bet on These ETFs | zacks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-16 | 2024-03 | 2.3 | N/A | N/A | N/A |
2024-02-28 | 2023-12 | 2.75 | 3.08 | 0.33 | 12.00% |
2023-11-21 | 2023-09 | 2.45 | 2.8 | 0.35 | 14.29% |
2023-08-22 | 2023-06 | 2.57 | 3.11 | 0.54 | 21.01% |
2023-05-16 | 2023-03 | 1.93 | 2.34 | 0.41 | 21.24% |
2023-02-22 | 2022-12 | 2.14 | 2.21 | 0.07 | 3.27% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-18 | JP Morgan | Upgrade | Overweight | Overweight |
2023-09-24 | Bernstein | Upgrade | Outperform | Outperform |
2023-08-30 | Benchmark | Upgrade | Buy | Buy |
2023-08-30 | Susquehanna | Upgrade | Positive | Positive |
2023-08-28 | Loop Capital | Upgrade | Buy | Buy |
2023-08-24 | JP Morgan | Upgrade | Overweight | Overweight |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Primecap Management Company | 9.29M | 1.27B | 3.28% |
2023-06-29 | Morgan Stanley | 3.28M | 449.55M | 1.16% |
2023-06-29 | Dodge & Cox Inc | 3.19M | 436.40M | 1.12% |
2023-06-29 | ARGA Investment Management, LP | 3.03M | 414.60M | 1.07% |
2023-06-29 | Ariel Investments, LLC | 2.76M | 377.36M | 0.97% |
2023-06-29 | Alkeon Capital Management LLC | 2.67M | 365.64M | 0.94% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard/Primecap Fund | 5.32M | 728.76M | 1.88% |
2023-06-29 | Dodge & Cox International Stock Fund | 2.35M | 321.57M | 0.83% |
2023-05-30 | Vanguard International Growth Fund | 1.95M | 239.76M | 0.69% |
2023-06-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 1.63M | 222.86M | 0.57% |
2023-06-29 | ACAP Strategic Fund | 1.29M | 176.45M | 0.45% |
2023-07-30 | Vanguard International Value Fund | 1.08M | 169.15M | 0.38% |
Split | Date |
---|---|
10 : 1 | 2010-05-12 |
For beginners in trading and investing, it's crucial to grasp that success in these fields goes beyond just technical analysis. Consistently investing over an extended period typically yields better results than attempting to time the market through short-term buying and selling based on fluctuations. Learning plays a vital role in achieving success in trading and investing. Staying updated on current trends and strategies can assist businesses in staying ahead of the curve and making well-informed decisions. I'm pleased that the insights and strategies have proven beneficial to me. Presently, I am generating $17,500 every ten days with my initial investment of $1,700. Feel free to reach out to Salome_crypto_trader via direct message on Instagram to kickstart your journey.https://www.instagram.com/salome_crypto_trader?igsh=MW5zOGdtb3lieGU3MQ==
$BIDU. Are people that dumb to think that these earnings are anything less than fantastic?? Idiotic. The same thing happened with $BABA. People don’t know how to read earnings, stock price dropped big on earnings day and recovered to the point the stock price is higher than prior to earnings. Same thing will happen here. Anyone selling will regret it later. Good luck.
Baidu (NASDAQ:BIDU) Upgraded to Buy by Nomura Instinet
→ Massive new discovery... (Ad)
Written by MarketBeat
November 22, 2023
SHARE
Baidu (NASDAQ:BIDU - Get Free Report) was upgraded by Nomura Instinet from a "neutral" rating to a "buy" rating in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a $145.00 price objective on the information services provider's stock. Nomura Instinet's target price would indicate a potential upside of 27.84% from the company's previous close.
Get Baidu alerts:
This internet stock is a must-have for your portfolio for 2024
Several other equities research analysts have also recently issued reports on the company. StockNews.com cut Baidu from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, October 25th. Loop Capital reduced their price objective on shares of Baidu from $215.00 to $190.00 and set a "buy" rating on the stock in a report on Tuesday, August 29th. Barclays lowered their target price on shares of Baidu from $183.00 to $138.00 and set an "overweight" rating for the company in a research note on Wednesday, November 1st. Citigroup lifted their price target on shares of Baidu from $181.00 to $182.00 and gave the company a "buy" rating in a research report on Wednesday, August 23rd. Finally, TheStreet cut shares of Baidu from a "b-" rating to a "c+" rating in a research report on Wednesday, October 25th. Seventeen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Baidu has an average rating of "Buy" and an average target price of $179.50.

$PTC Therapeutics(PTCT.US)$ Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.